Salvage bortezomib–dexamethasone and high-dose melphalan (HDM) and autologous stem cell support (ASCT) in myeloma patients at first relapse after HDM with ASCT. A phase-2 trial

Until recently, only retrospective studies had been published on salvage high-dose melphalan (HDM) with autologous stem cell ‘transplantation' (ASCT). In a prospective, nonrandomized phase-2 study, we treated 53 bortezomib-naïve patients with bortezomib–dexamethasone as induction and bortezomib...

Descripción completa

Detalles Bibliográficos
Autores principales: Gimsing, P, Hjertner, Ø, Abildgaard, N, Andersen, N F, Dahl, T G, Gregersen, H, Klausen, T W, Mellqvist, U-H, Linder, O, Lindås, R, Tøffner Clausen, N, Lenhoff, S
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2015
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4598614/
https://www.ncbi.nlm.nih.gov/pubmed/26121108
http://dx.doi.org/10.1038/bmt.2015.125

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4598614/
https://www.ncbi.nlm.nih.gov/pubmed/26121108
http://dx.doi.org/10.1038/bmt.2015.125

Ejemplares similares